A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC

Mutant KRAS represents one of the most frequently observed oncogenes in NSCLC, yet no therapies are approved for tumors that express activated KRAS variants. While there is strong rationale for the use of MEK inhibitors to treat tumors with activated RAS/MAPK signaling, these have proven ineffective...

Descripción completa

Detalles Bibliográficos
Autores principales: Dompe, Nicholas, Klijn, Christiaan, Watson, Sara A., Leng, Katherine, Port, Jenna, Cuellar, Trinna, Watanabe, Colin, Haley, Benjamin, Neve, Richard, Evangelista, Marie, Stokoe, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005515/
https://www.ncbi.nlm.nih.gov/pubmed/29912950
http://dx.doi.org/10.1371/journal.pone.0199264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005515/
https://www.ncbi.nlm.nih.gov/pubmed/29912950
http://dx.doi.org/10.1371/journal.pone.0199264

Ejemplares similares